MAGEA3: Difference between revisions

Jump to navigation Jump to search
m (Bot: HTTP→HTTPS)
imported>Citation bot
m (Alter: title, issue. Add: format, url. Removed parameters. You can use this bot yourself. Report bugs here. | Anas1712)
 
Line 8: Line 8:
== Function and Clinical relevance ==
== Function and Clinical relevance ==


The normal function of MAGE-A3 in healthy cells is unknown.<ref name="pmid22156658">{{cite journal |vauthors=Decoster L, Wauters I, Vansteenkiste JF | title = Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. | journal = Annals of Oncology | volume = 23 | issue =  | pages = 1387–1393 |date=Dec 2011 | pmid = 22156658 | pmc = | doi = 10.1093/annonc/mdr564 }}</ref> The presence of the antigen on tumor cells has been associated with worse prognosis. In one study, high levels of MAGE-A3 in [[lung adenocarcinoma]] were associated with shorter survival.<ref name="pmid16299236">{{cite journal |author1=Ali O. Gure |author2=Ramon Chua |author3=Barbara Williamson |author4=Mithat Gonen |author5=Cathy A. Ferrera |author6=Sacha Gnjatic |author7=Gerd Ritter |author8=Andrew J.G. Simpson |author9=Yao-T. Chen |author10=Lloyd J. Old |author11=Nasser K. Altorki | title = Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer | journal = Clinical Cancer Research | volume = 11 | issue = 22 | pages = 8055–8062 |date=Nov 2005 | pmid = 16299236 | pmc = | doi =  10.1158/1078-0432.CCR-05-1203 }}</ref>
The normal function of MAGE-A3 in healthy cells is unknown.<ref name="pmid22156658">{{cite journal |vauthors=Decoster L, Wauters I, Vansteenkiste JF | title = Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development | journal = Annals of Oncology | volume = 23 | issue =  6| pages = 1387–1393 |date=Dec 2011 | pmid = 22156658 | pmc = | doi = 10.1093/annonc/mdr564 }}</ref> The presence of the antigen on tumor cells has been associated with worse prognosis. In one study, high levels of MAGE-A3 in [[lung adenocarcinoma]] were associated with shorter survival.<ref name="pmid16299236">{{cite journal |author1=Ali O. Gure |author2=Ramon Chua |author3=Barbara Williamson |author4=Mithat Gonen |author5=Cathy A. Ferrera |author6=Sacha Gnjatic |author7=Gerd Ritter |author8=Andrew J.G. Simpson |author9=Yao-T. Chen |author10=Lloyd J. Old |author11=Nasser K. Altorki | title = Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer | journal = Clinical Cancer Research | volume = 11 | issue = 22 | pages = 8055–8062 |date=Nov 2005 | pmid = 16299236 | pmc = | doi =  10.1158/1078-0432.CCR-05-1203 }}</ref>


MAGE-A3 is a tumor-specific protein, and has been identified on many tumors including [[melanoma]], [[non-small cell lung cancer]], [[hematologic malignancies]], among others.<ref>{{cite web|author=Corporate Comms |url=http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10076.htm |title=New data on MAGE-A3 cancer immunotherapy support potential novel options of treating non-small cell lung cancer and melanoma |publisher=Us.gsk.com |date= |accessdate=2012-10-16}}</ref> Currently, [[GlaxoSmithKline]] is developing a [[cancer vaccine]] targeting MAGE-A3.  The vaccine is a fusion protein of MAGE-A3 and ''[[Haemophilus influenzae]]'' [[protein D]], combined with a proprietary immunoadjuvant.<ref>{{cite web|url=http://www.google.com/patents/US20100008980 |title=Patent US20100008980 - Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with ... - Google Patents |publisher=Google.com |date=2008-01-08 |accessdate=2012-10-16}}</ref>
MAGE-A3 is a tumor-specific protein, and has been identified on many tumors including [[melanoma]], [[non-small cell lung cancer]], [[hematologic malignancies]], among others.<ref>{{cite web |author=Corporate Comms |url=http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10076.htm |title=New data on MAGE-A3 cancer immunotherapy support potential novel options of treating non-small cell lung cancer and melanoma |publisher=Us.gsk.com |date= |accessdate=2012-10-16 |deadurl=yes |archiveurl=https://web.archive.org/web/20120627085442/http://us.gsk.com/html/media-news/pressreleases/2008/2008_us_pressrelease_10076.htm |archivedate=2012-06-27 |df= }}</ref> Currently, [[GlaxoSmithKline]] is developing a [[cancer vaccine]] targeting MAGE-A3.  The vaccine is a fusion protein of MAGE-A3 and ''[[Haemophilus influenzae]]'' [[protein D]], combined with a proprietary immunoadjuvant.<ref>{{cite web|url=http://www.google.com/patents/US20100008980 |title=Patent US20100008980 - Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with ... - Google Patents |date=2008-01-08 |accessdate=2012-10-16}}</ref>


== References ==
== References ==
Line 17: Line 17:
==Further reading==
==Further reading==
{{refbegin | 2}}
{{refbegin | 2}}
*{{cite journal  |vauthors=Brasseur F, Rimoldi D, Liénard D, etal |title=Expression of MAGE genes in primary and metastatic cutaneous melanoma. |journal=Int. J. Cancer |volume=63 |issue= 3 |pages= 375–80 |year= 1995 |pmid= 7591235 |doi=10.1002/ijc.2910630313  }}
*{{cite journal  |vauthors=Brasseur F, Rimoldi D, Liénard D, etal |title=Expression of MAGE genes in primary and metastatic cutaneous melanoma |journal=Int. J. Cancer |volume=63 |issue= 3 |pages= 375–80 |year= 1995 |pmid= 7591235 |doi=10.1002/ijc.2910630313  }}
*{{cite journal  |vauthors=Kocher T, Schultz-Thater E, Gudat F, etal |title=Identification and intracellular location of MAGE-3 gene product. |journal=Cancer Res. |volume=55 |issue= 11 |pages= 2236–9 |year= 1995 |pmid= 7757970 |doi=  }}
*{{cite journal  |vauthors=Kocher T, Schultz-Thater E, Gudat F, etal |title=Identification and intracellular location of MAGE-3 gene product |journal=Cancer Res. |volume=55 |issue= 11 |pages= 2236–9 |year= 1995 |pmid= 7757970 |doi=  }}
*{{cite journal  |vauthors=De Plaen E, Arden K, Traversari C, etal |title=Structure, chromosomal localization, and expression of 12 genes of the MAGE family. |journal=Immunogenetics |volume=40 |issue= 5 |pages= 360–9 |year= 1994 |pmid= 7927540 |doi=10.1007/BF01246677  }}
*{{cite journal  |vauthors=De Plaen E, Arden K, Traversari C, etal |title=Structure, chromosomal localization, and expression of 12 genes of the MAGE family |journal=Immunogenetics |volume=40 |issue= 5 |pages= 360–9 |year= 1994 |pmid= 7927540 |doi=10.1007/BF01246677  }}
*{{cite journal  |vauthors=Ding M, Beck RJ, Keller CJ, Fenton RG |title=Cloning and analysis of MAGE-1-related genes. |journal=Biochem. Biophys. Res. Commun. |volume=202 |issue= 1 |pages= 549–55 |year= 1994 |pmid= 8037761 |doi= 10.1006/bbrc.1994.1963 }}
*{{cite journal  |vauthors=Ding M, Beck RJ, Keller CJ, Fenton RG |title=Cloning and analysis of MAGE-1-related genes |journal=Biochem. Biophys. Res. Commun. |volume=202 |issue= 1 |pages= 549–55 |year= 1994 |pmid= 8037761 |doi= 10.1006/bbrc.1994.1963 |url=https://zenodo.org/record/1229420 |format=Submitted manuscript }}
*{{cite journal  |vauthors=Gaugler B, Van den Eynde B, van der Bruggen P, etal |title=Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes |journal=J. Exp. Med. |volume=179 |issue= 3 |pages= 921–30 |year= 1994 |pmid= 8113684 |doi=10.1084/jem.179.3.921  | pmc=2191409  }}
*{{cite journal  |vauthors=Gaugler B, Van den Eynde B, van der Bruggen P, etal |title=Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes |journal=J. Exp. Med. |volume=179 |issue= 3 |pages= 921–30 |year= 1994 |pmid= 8113684 |doi=10.1084/jem.179.3.921  | pmc=2191409  }}
*{{cite journal  |vauthors=Maruyama K, Sugano S |title=Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides |journal=Gene |volume=138 |issue= 1–2 |pages= 171–4 |year= 1994 |pmid= 8125298 |doi=10.1016/0378-1119(94)90802-8  }}
*{{cite journal  |vauthors=Maruyama K, Sugano S |title=Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides |journal=Gene |volume=138 |issue= 1–2 |pages= 171–4 |year= 1994 |pmid= 8125298 |doi=10.1016/0378-1119(94)90802-8  }}

Latest revision as of 22:32, 5 September 2018

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Melanoma-associated antigen 3 (MAGE-A3) is a protein that in humans is encoded by the MAGEA3 gene.[1][2][3]

Genetics

This gene is a member of the melanoma-associated antigen gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita.[3]

Function and Clinical relevance

The normal function of MAGE-A3 in healthy cells is unknown.[4] The presence of the antigen on tumor cells has been associated with worse prognosis. In one study, high levels of MAGE-A3 in lung adenocarcinoma were associated with shorter survival.[5]

MAGE-A3 is a tumor-specific protein, and has been identified on many tumors including melanoma, non-small cell lung cancer, hematologic malignancies, among others.[6] Currently, GlaxoSmithKline is developing a cancer vaccine targeting MAGE-A3. The vaccine is a fusion protein of MAGE-A3 and Haemophilus influenzae protein D, combined with a proprietary immunoadjuvant.[7]

References

  1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (Jan 1992). "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma". Science. 254 (5038): 1643–7. doi:10.1126/science.1840703. PMID 1840703.
  2. Rogner UC, Wilke K, Steck E, Korn B, Poustka A (Mar 1996). "The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28". Genomics. 29 (3): 725–31. doi:10.1006/geno.1995.9945. PMID 8575766.
  3. 3.0 3.1 "Entrez Gene: MAGEA3 melanoma antigen family A, 3".
  4. Decoster L, Wauters I, Vansteenkiste JF (Dec 2011). "Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development". Annals of Oncology. 23 (6): 1387–1393. doi:10.1093/annonc/mdr564. PMID 22156658.
  5. Ali O. Gure; Ramon Chua; Barbara Williamson; Mithat Gonen; Cathy A. Ferrera; Sacha Gnjatic; Gerd Ritter; Andrew J.G. Simpson; Yao-T. Chen; Lloyd J. Old; Nasser K. Altorki (Nov 2005). "Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer". Clinical Cancer Research. 11 (22): 8055–8062. doi:10.1158/1078-0432.CCR-05-1203. PMID 16299236.
  6. Corporate Comms. "New data on MAGE-A3 cancer immunotherapy support potential novel options of treating non-small cell lung cancer and melanoma". Us.gsk.com. Archived from the original on 2012-06-27. Retrieved 2012-10-16.
  7. "Patent US20100008980 - Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with ... - Google Patents". 2008-01-08. Retrieved 2012-10-16.

Further reading